HealthCap
HealthCap
  • About
    • Our Story
    • Strategy
    • ESG Policy
    • Partners
    • Team
    • Special Advisors
  • 1996 – 2021
  • Investments
    • Portfolio Companies
    • Approved Products
  • News
    • Portfolio Companies
    • HealthCap
  • Contact & Legal
    • Contact Us
    • Privacy Policy
    • Cookie Policy
  • LinkedIn
  • Twitter
  • Wikipedia
HealthCap

HealthCap is a family of venture capital funds investing globally in life sciences. With more than EUR 1.2 billion raised since the start in 1996, HealthCap is one of the largest specialized providers of venture capital within life sciences in Europe.

Read more

Portfolio Companies News

  • August 11, 2022
    Oncopeptides publishes Q2 report 20...

    STOCKHOLM — August 11, 2022 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, today publishes the report for the second quarter 2022. “CHMPs recommendation to grant Pepaxti a ... read more

  • August 11, 2022
    Targovax ASA: Invitation to Targova...

    Oslo, Norway, 11 August 2022 – Targovax ASA (OSE: TRVX) will announce its second quarter and first half 2022 results on Thursday 18 August 2022. Targovax’s management will present the results at a live streamed webcast at 10:00 am CET to investors, analysts and the press. The results report ... read more

  • August 10, 2022
    Aro Biotherapeutics Receives FDA Or...

    PHILADELPHIA, PA., AUGUST 10, 2022 – Aro Biotherapeutics, a biotechnology company pioneering the development of tissue-targeted genetic medicines, today announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation for ABX1100, an investigational Centyrin-siRNA conjug... read more

  • August 10, 2022
    Spruce Biosciences Reports Second Q...

    Abstract Accepted for Oral Presentation at International Congress of Endocrinology (ICE 2022) Appointment of P.J. Ramtin as Senior Vice President of Business Operations Expansion of Tildacerfont Patent Portfolio Estate with Key Method of Use Patents ... read more

  • August 9, 2022
    Fusion Pharmaceuticals Announces Se...

    FPI-2059 IND cleared by FDA; Clinical portfolio expanded to include small molecule-based targeted alpha therapy Data supporting ongoing evaluation of cold antibody pre-administration dosing regimen in Phase 1 study of FPI-1434 presented at SNMMI 2022 Annual Meeting Company strengthens actiniu... read more

HealthCap Info

  • July 26, 2022
    Q2 2022 General Market Overview
  • October 07, 2021
    HealthCap strengthens senior team
  • November 29, 2021
    HealthCap’s 25th company anniversary!

Facts

  • 126

    Since the start in 1996, HealthCap funds have invested in 126 portfolio companies.

    Read more
  • 46

    46 of the portfolio companies have been taken public on fourteen different markets.

    Read more
  • 31

    31 of the portfolio companies pharmaceutical products have been approved for marketing.

    Read more
  • 12

    Unicorn Factory
    Since the start in 1996, HealthCap has helped build 12 companies with a valuation of USD 1 billion or more.

    Read more

Twitter

Aro Biotherapeutics Receives FDA Orphan Drug Designation for ABX1100 for the Treatment of Pompe Disease @HealthCapVC
16 hours ago
InCarda Therapeutics Announces Enrollment of First Patient in Pivotal Phase 3 RESTORE-1 Trial of InRhythm™ for the… @HealthCapVC
15 days ago

Subscribe to news

Venture Capital for Breakthrough Therapies

This site uses cookies. But first we need your consent. More info.

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close